Plot No. 32, Sector 5, IMT Manesar, Gurgaon, Haryana 122052, India
For collaboration/partnership/services/feedback, we would like to hear your thoughts
LeadInvent has been awarded a project under BIRAP CRS Scheme March 2013. The CRS scheme is an initiative of Biotechnology Industry Research Assistance Programme (BIRAP), Department of Biotechnolgy (DBT), Government of India. CRS initiative is to supports academia-industry interaction between research institutes, universities, public funded research laboratories, governmental organizations, research foundations and companies / industries under a Public-Private Partnership (PPP) mode. The project "Using Peptidomimetics to design small molecules from a novel P1 peptide, for its interaction with beta amyloid oligomers by in-silico, in-vitro approaches and its efficiency in clearing beta amyloid load by ex-vivo model of Alzheimers disease" is to be carried out by University of Delhi South Campus along with National Brain Research Centre and LeadInvent Technologies Current treatments only help with the symptoms of the disease. There are no available treatments that stop or reverse the progression of the disease. As of 2012, more than 1,000 clinical trials have been or are being conducted to test various compounds in AD.
LeadInvent, dedicated to developing new methodologies and products for viable therapeutic lead molecules. A team of scientists working since 2002 at the Supercomputing Facility for Bioinformatics and Computational Biology at the Indian Institute of Technology (IIT), New Delhi, one of the finest engineering institutes of India, felt the need to share the research available at the institute with the world.
A multitude of factors have been cited as impeding progress in finding a cure for cancer and activation of alternate pathway is one of them. To combat this problem LeadInvent, Sphaera Pharma and ICGEB has been awarded project under DBT-BIPP scheme entitled “Novel combination therapy for treatment of resistant and non-responsive cancers (Phase-I).
Distinct patterns of resistance have evolved with the use of drugs targeting cancer therapeutic protein, and its mutations, which alter drug binding or favor protein conformations inaccessible to drugs, are a common finding associated with clinical resistance. Many reasons are provided for these resistances (intrinsic or acquired). One the prime reason is the activation of alternate pathway in the cell. To overcome this problem many companies are going for combination therapy or developing dual inhibitors.
A team of scientists working since 2002 at the Supercomputing Facility for Bioinformatics and Computational Biology in the Indian Institute of Technology (IIT), New Delhi, one of the finest engineering institutes of India, felt the need to share the research available at IIT with the world. The idea was to create a platform that enables researchers and scientists across the industry to use algorithms developed at IIT for their research.
LeadInvent has been awarded a project under DBT Small Business Innovation Research Initiative (SBIRI) Scheme. The SBIRI scheme is an initiative of Department of Biotechnology (DBT), Government of India. SBIRI scheme was launched in 2005 to boost Public-Private-Partnership (PPP) efforts in the country. SBIRI was the first of its kind, early stage, innovation focused PPP initiative in the area of Biotechnology.
The project “Computational design & development of inhibitors for the treatment of Tuberculosis (Phase I)” is to be carried out by LeadInvent Technologies along with AIIMS. The Aim of the project is to find methods of inhibiting latent bacteria and rendering them harmless.